Literature DB >> 4138646

Immunization against Pseudomonas in infection after thermal injury.

J Wesley, A Fisher, M W Fisher.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4138646     DOI: 10.1093/infdis/130.supplement.s152

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  26 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

4.  [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].

Authors:  J E Pennington; G B Pier
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  Structural elucidation of the lipopolysaccharide core region of the O-chain-deficient mutant strain A28 from Pseudomonas aeruginosa serotype 06 (International Antigenic Typing Scheme).

Authors:  H Masoud; I Sadovskaya; T de Kievit; E Altman; J C Richards; J S Lam
Journal:  J Bacteriol       Date:  1995-12       Impact factor: 3.490

6.  Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice.

Authors:  C L Pierson; A G Johnson; I Feller
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

7.  Reaginic antibody production to protein antigens of Escherichia coli and Pseudomonas aeruginosa by mice.

Authors:  P J Danneman; J G Michael
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

8.  Pseudomonas aeruginosa R factors determining gentamicin plus carbenicillin resistance from patients with urinary tract colonizations.

Authors:  T R Korfhagen; J C Loper; J A Ferrel
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

9.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

10.  Cross-protection of mice provided by active and passive immunization against experimental infections with virulent Proteus rettgeri and Providencia bacteria.

Authors:  J L Penner; G R Whiteley
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.